222 Serial Monitoring of Viral Load and Serum Alanine Aminotranferase Level and the Risk of Hepatocellular Carcinoma: R.E.V.E.a.L.-HBV Study Update

Chen, Chien-Jen; Yang, Hwai‐I; Su, Jun; Jen, C.-L.; You, San–Lin; Chen, Chuen‐Fei; Iloeje, Uchenna H.

doi:10.1016/s0016-5085(08)63540-4

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is therefore likely that the baseline HBV DNA reflects a long duration of HBV DNA elevation in a subset of patients, a large number of whom have gone through the immune clearance phase (85% were HBeAg-negative) without successfully clearing the virus; these subjects are understood to remain at risk for future hepatic inflammation/fibrosis. Supporting evidence for this comes from subsequent analyses of this cohort; first, in a subsequent time dependent analyses including information on multiple HBV DNA time point, the results observed using the single baseline HBV DNA were confirmed (39). Secondly, in the analyses of HCC risk as determined by the changes in serum HBV DNA levels over the follow-up period, we observed an association between the HBV DNA trajectory and the changes in serum ALT level over time (40,41).…”

Section: Revelations Insights and Questions From The Reveal-hbv Studymentioning

confidence: 60%

Natural history of chronic hepatitis B: what exactly has REVEAL Revealed?

Iloeje

Yang

Chen

2012

Liver International

Self Cite

103

View full text Add to dashboard Cite

Chronic hepatitis B virus (HBV) infection is a serious public health problem because of its worldwide prevalence and potential to cause adverse consequences. The Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-Hepatitis B Virus (REVEAL-HBV) study carried out in Taiwan was used to investigate the natural history of chronic hepatitis B. The REVEAL-HBV study has established an HBV viral load paradigm in the natural history of chronic hepatitis B (CHB). Serum HBV DNA level has been shown to be significantly and independently associated with incidence of hepatocellular carcinoma (HCC) and cirrhosis and liver-related mortality across a biological gradient. It is also a major predictor of HBsAg seroclearance. Genetic features including HBV genotype and basal core promoter A1762T/G1764A mutant, and precore G1896A mutant were documented as predictors of HCC risk. Inactive HBV carriers still had an increased risk on HCC development and liver-related mortality compared with HBsAg -seronegatives. Nomograms focusing on facilitating risk communication between patients and clinicians were developed incorporating non-invasive clinical parameters to predict long-term HCC risk. These will hopefully contribute to evidence-based decisions in the clinical management of CHB patients. A somewhat provocative and novel finding from the REVEAL-HBV study is the association of chronic HBV infection in active replication with an increased pancreatic cancer risk especially in women less than 50 years old. This finding will hopefully spur further research in this area seeking confirmatory evidence. Finally, we hope that the REVEAL-HBV study will continue to be a source of data to answer other important questions in chronic hepatitis B research going forward. Background and overview

show abstract

Section: Revelations Insights and Questions From The Reveal-hbv Studymentioning

confidence: 60%